Apogee Therapeutics Inc. (APGE)
NASDAQ: APGE
· Real-Time Price · USD
36.93
-0.36 (-0.97%)
At close: Aug 18, 2025, 3:59 PM
36.90
-0.08%
After-hours: Aug 18, 2025, 05:31 PM EDT
-0.97% (1D)
| Bid | 35.5 |
| Market Cap | 2.2B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -150.05M |
| EPS (ttm) | -4.14 |
| PE Ratio (ttm) | -8.92 |
| Forward PE | -6.42 |
| Analyst | Buy |
| Ask | 38.9 |
| Volume | 251,009 |
| Avg. Volume (20D) | 895,172 |
| Open | 37.37 |
| Previous Close | 37.29 |
| Day's Range | 36.46 - 37.95 |
| 52-Week Range | 26.20 - 63.50 |
| Beta | 1.44 |
About APGE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol APGE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for APGE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-17.32%
APGE stock has given up its prior gain. Apogee The...
Unlock content with
Pro Subscription
1 month ago
-17.32%
Apogee Therapeutics shares are trading higher after the company released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.
1 month ago · proactiveinvestors.com
Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drugApogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The tr...
